Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

64.99 -0.95 (-1.44%)
Streaming Delayed Price Updated: 10:39 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Prioritizing the Needs of the Black LGBTQ+ Community in an Innovative HIV Trial
SOURCE: Gilead Sciences 
Via 3BL Media
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
From Gilead Sciences, Inc.
Via Business Wire
New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor
From Gilead Sciences, Inc.
Via Business Wire
Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021
From Gilead Sciences, Inc.
Via Business Wire
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada's National Research Council
VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs 
Via TheNewswire.com
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Gilead to Present New Data at IAS 2021 Demonstrating the Company’s Commitment to Advancing Innovation in HIV Research
From Gilead Sciences, Inc.
Via Business Wire
BA Insight Named to KMWorld AI 50
Recognized as a Company that Empowers Intelligent Knowledge ManagementBOSTON - July 15, 2021 - PRLog -- BA Insight is pleased to announce that it has been named to the KMWorld AI 50, which shines light... 
Via PRLog
Topics Artificial Intelligence
Exposures Artificial Intelligence
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
From Gilead Sciences, Inc.
Via Business Wire
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Regenerative Medicine Market Size to Reach Revenues of over USD 27 Billion by 2026 – Arizton
The global regenerative medicine market size is estimated to reach USD 27.08 billion by 2026, growing at a CAGR of 30% during the forecast period. 
Via EIN Presswire
Topics Death
Exposures COVID-19 Death Product Safety
Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
From Gilead Sciences, Inc.
Via Business Wire
Coronavirus Vaccine Investment Market to See Massive Growth by 2026 : Serum Institute of India, BioNTech SE Pfizer, Gilead Sciences
Coronavirus Vaccine Investment Comprehensive Study by Type (Government, Private Firms), Application (Hospitals, Research Laboratories, Clinics, Others) Players and Region - Global Market Outlook to... 
Via SBWire
Exposures COVID-19
Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China
From Gilead Sciences, Inc.
Via Business Wire
Adonis Timone Aims to Create Change With Advocates for Youth
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
From Gilead Sciences, Inc.
Via Business Wire
Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies
From Gilead Sciences, Inc.
Via Business Wire
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19 Product Safety
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
New York, New York--(Newsfile Corp. - June 17, 2021) - PCG Digital -- Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a... 
Via Newsfile
Exposures COVID-19 Product Safety
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 
Via TheNewswire.com
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
It's Time to Pass the Equality Act
SOURCE: Gilead Sciences 
Via 3BL Media
Topics LGBTQ
Exposures Diversity
Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis
From Kite, a Gilead Company
Via Business Wire
U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
From Gilead Sciences, Inc.
Via Business Wire
Pharmaceutical Drugs Market Projected to Show Strong Growth : Pfizer, Bayer, Sanofi
Keep yourself up-to-date with latest market trends and maintain a competitive edge by sizing up with available business opportunity in Pharmaceutical Drugs Market various segments and emerging... 
Via SBWire
Topics Supply Chain
Exposures Supply Chain
BIO Takes on Health Equity in Clinical Trials
First-ever BIO Clinical Trial Diversity Summit will engage stakeholders to build a sustainable and equitable clinical development ecosystem 
Via EIN Presswire
Reducing Our Footprint: It's Time to Get More Ambitious
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Climate Change Emissions Supply Chain
Exposures Climate Supply Chain
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation
From Gilead Sciences, Inc.
Via Business Wire
ICAN Obtains And Releases Nearly 3,000 Fauci Emails From The Beginning Of The Pandemic; Twitter Account suspended
FOIA ruling releases almost 3,000 emails from Anthony Fauci to the public. 
Via EIN Presswire
Topics Death Lawsuit
Exposures COVID-19 Death Financial
Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.